OMRON Contributes JPY7.854M to the iPS Cell Research Fund via the Shareholder Benefit Program

• September 09, 2020

OMRON Corporation (HQ: Shimogyo-Ku, Kyoto; President CEO: Yoshihito Yamada) announced today that it will donate 7,854,000 yen, which was collected via the fiscal 2020 Shareholder Benefit Program, to Kyoto University Fund, iPS Cell Research Fund. A total of 2,310 applications were filed within a month before the window was closed at the end of June, which surpassed the previous record of 2,130 applications amounting to 6,730,000 yen in fiscal 2019. The gift will be utilized to support iPS cells' medical applications and innovative research, employment of researchers and research support staff, and establishment and protection of intellectual properties on iPS cells, etc.

Launched in 2013, OMRON's Shareholder Benefit Program has allowed its shareholders to choose donation, OMRON Healthcare devices, or other items in accordance with the number of shares held. Beginning in fiscal 2018, the iPS Cell Research Fund has been chosen as the sole recipient of the donations, a reflection of OMRON's support for the Center for iPS Cell Research and Application, Kyoto University (Location: Sakyo-ku, Kyoto; Director: Shinya Yamanaka, MD, PhD) in their endeavor to the rapid development of iPS cell-based therapies or to deliver the benefits of iPS cell research as quickly as possible to patients.

True to our mission of continuing to contribute to a sustainable society, we at OMRON will remain committed to contribute to a better society through a variety of programs.

About Kyoto University Fund, iPS Cell Research Fund
The iPS Cell Research Fund was established under the Kyoto University Fund in April 2009 with a view toward accelerating the efforts of Kyoto University's Center for iPS Cell Research and Application (CiRA) by enabling them to work seamlessly to conduct research ranging from basic to applied, thereby making the fruit of iPS cell research available for social causes without delay.

For details, please visit: http://www.cira.kyoto-u.ac.jp/e/about/fund.html

Key Reasons for Selecting the iPS Cell Research Fund as the Recipient

1. CiRA is engaged in research activity towards its mission of achieving the clinical application of iPS cells that will result in solving social issues. Their aim corresponds to the OMRON Principles and its key practices to "contribute to help realize healthy and comfortable lives for people around the world."
2. By adding the iPS Cell Research Fund to the list of options for the Shareholder Benefit Program, we can invite our shareholders to empathize with our efforts to live up to the OMRON Principles and assist CiRA's research for practical application of iPS cells by giving to the fund.
3. Being a corporate citizen of Kyoto, we can contribute to the development of the local community by supporting advanced scientific research and innovative research by the Kyoto-based university.

OMRON's company's shareholder benefit program will end at this time. For details, please visit below website: https://www.omron.com/global/en/assets/file/ir/irlib/20200728_notice_e.pdf

About OMRON

As a leading company of automation centered on its proprietary Sensing & Control + Think technologies, OMRON Corporation is engaged in a wide range of businesses, including control equipment, electronic components, social systems, healthcare, and the environment. OMRON, founded in 1933, has approximately 30,000 employees worldwide and provides products and services in approximately 120 countries and regions. Refer to https://www.omron.com for more information.